Invivyd (IVVD) Change in Accured Expenses (2021 - 2025)
Invivyd posted quarterly Change in Accured Expenses of -$6.0 million for Q4 2025, up 62.49% year-on-year from -$3.7 million in Q4 2024, and up 75.77% on a QoQ basis from -$24.8 million in Q3 2025.
Invivyd (IVVD) has 5 years of Change in Accured Expenses data on file, last reported at -$6.0 million in Q4 2025.
- For the quarter ending Q4 2025, Change in Accured Expenses rose 62.49% year-over-year to -$6.0 million; the trailing twelve-month figure through Dec 2025 stood at -$30.8 million (down 385487.5% YoY), and the FY2025 full-year result was -$30.8 million, down 385487.5% from the prior year.
- Change in Accured Expenses for Q4 2025 stood at -$6.0 million, up from -$24.8 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $20.3 million in Q1 2022 and bottomed at -$30.1 million in Q4 2021.
- The 5-year median for Change in Accured Expenses is -$3.0 million (2023), against an average of -$3.3 million.
- Peak annual rise in Change in Accured Expenses reached 248.77% in 2024, while the deepest fall reached 53669.23% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at -$30.1 million in 2021, then soared by 75.72% to -$7.3 million in 2022, then soared by 174.42% to $5.4 million in 2023, then tumbled by 394.74% to -$16.0 million in 2024, then surged by 62.49% to -$6.0 million in 2025.
- The last three Change in Accured Expenses figures came in at -$6.0 million (Q4 2025), -$24.8 million (Q3 2025), and $10.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | -6.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.02 Mn |
| Dec 31, 2025 | -6.02 Mn |
| Sep 30, 2025 | -24.83 Mn |
| Sep 30, 2025 | -24.83 Mn |
| Jun 30, 2025 | 10.01 Mn |
| Jun 30, 2025 | 10.01 Mn |
| Mar 31, 2025 | -10.01 Mn |
| Mar 31, 2025 | -10.01 Mn |
| Dec 31, 2024 | -16.04 Mn |
| Dec 31, 2024 | -16.04 Mn |
| Sep 30, 2024 | 16.05 Mn |
| Sep 30, 2024 | 16.05 Mn |
| Jun 30, 2024 | 6.95 Mn |
| Jun 30, 2024 | 6.95 Mn |
| Mar 31, 2024 | -6.96 Mn |
| Mar 31, 2024 | -6.96 Mn |
| Dec 31, 2023 | 5.44 Mn |
| Dec 31, 2023 | 5.44 Mn |
| Sep 30, 2023 | -10.79 Mn |
| Sep 30, 2023 | -10.79 Mn |
| Jun 30, 2023 | 5.32 Mn |
| Jun 30, 2023 | 5.32 Mn |
| Mar 31, 2023 | 13,000.00 |
| Mar 31, 2023 | 13,000.00 |
| Dec 31, 2022 | -7.31 Mn |
| Dec 31, 2022 | -7.31 Mn |
| Sep 30, 2022 | -27.61 Mn |
| Sep 30, 2022 | -27.61 Mn |
| Jun 30, 2022 | -20.20 Mn |
| Jun 30, 2022 | -20.20 Mn |
| Mar 31, 2022 | 20.26 Mn |
| Mar 31, 2022 | 20.26 Mn |
| Dec 31, 2021 | -30.12 Mn |
| Dec 31, 2021 | -30.12 Mn |
| Sep 30, 2021 | 9.07 Mn |
| Sep 30, 2021 | 9.07 Mn |
| Jun 30, 2021 | 8.67 Mn |
| Jun 30, 2021 | 8.67 Mn |
| Mar 31, 2021 | 12.39 Mn |
| Mar 31, 2021 | 12.39 Mn |